Last reviewed · How we verify

Aselend — Competitive Intelligence Brief

Aselend (SODIUM SELENITE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sodium selenite. Area: Immunology.

discontinued sodium selenite Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Aselend (SODIUM SELENITE) — Fujimoto Pharmaceutical Corporation. Aselend works by providing the body with selenium, an essential mineral that plays a crucial role in various bodily functions.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aselend TARGET SODIUM SELENITE Fujimoto Pharmaceutical Corporation discontinued sodium selenite

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sodium selenite class)

  1. Fujimoto Pharmaceutical Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aselend — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-selenite. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing